bftc909 cells (Guangzhou JET Bio-Filtration)
Structured Review

Bftc909 Cells, supplied by Guangzhou JET Bio-Filtration, used in various techniques. Bioz Stars score: 99/100, based on 90 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/inserts/pmc13040342-90-7-21?v=Guangzhou+JET+Bio-Filtration
Average 99 stars, based on 90 article reviews
Images
1) Product Images from "Pre-Treatment BOC Expression as an Indicator of Lymphovascular Invasion and In Vitro Chemotherapeutic Response in Upper Tract Urothelial Carcinoma"
Article Title: Pre-Treatment BOC Expression as an Indicator of Lymphovascular Invasion and In Vitro Chemotherapeutic Response in Upper Tract Urothelial Carcinoma
Journal: Oncology Research
doi: 10.32604/or.2026.070837
Figure Legend Snippet: BOC silencing suppresses cell migration in urothelial carcinoma cells. ( A ) qRT-PCR confirmed efficient knockdown of BOC expression in BFTC909 cells using two independent shRNAs (**, p < 0.01, one-way ANOVA). ( B–D ) Representative images and quantification of Boyden chamber assays demonstrated significantly decreased migration in shBOC cells compared with controls (***, p < 0.001, one-way ANOVA). Scale bar: 200 µm, ( E,F ) RTCA migration assays showed impaired migration of BFTC909 cells after BOC knockdown (***, p < 0.001, two-way ANOVA with repeated measures and post-hoc tests).
Techniques Used: Migration, Quantitative RT-PCR, Knockdown, Expressing
Figure Legend Snippet: BOC silencing enhances sensitivity to cisplatin and gemcitabine in BFTC909 cells. ( A – D ) Cell viability assays were performed in BFTC909 cells with BOC knockdown (shBOC#1) or control (shScramble) following treatment with ( A ) cisplatin, ( B ) gemcitabine, ( C ) paclitaxel, or ( D ) epirubicin at the indicated concentrations. Data are presented as mean ± SEM. All statistics were determined using the one-way ANOVA. **, p < 0.01; ***, p < 0.001; ns, not significant.
Techniques Used: Knockdown, Control
